Studies Further Validate Safety, Efficacy and an Improved Patient Experience in Use of the C2 Cryoballoon® Ablation System for Primary Treatment of Barrett’s Esophagus

//Studies Further Validate Safety, Efficacy and an Improved Patient Experience in Use of the C2 Cryoballoon® Ablation System for Primary Treatment of Barrett’s Esophagus

REDWOOD CITY, Calif. – May 9, 2017 – C2 Therapeutics marked Digestive Disease Week by releasing the results of clinical studies that help further validate the utility of the C2 CryoBalloon®  Ablation System (CbAS) for ablation of Barrett’s esophagus.

C2 CryoBalloon Focal Ablation System is intended for use as a cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett’s esophagus with dysplasia.

Click here to see full release.

2017-05-16T21:29:57+00:00